Robert Cotes
Overview
Robert O. Cotes, MD, is a Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences.
Dr. Cotes is Chief of Psychiatry at Grady Health System. He is the founder and Co-Director of the Clinical & Research Program for Psychosis at Grady Health System, which comprises of three clinical programs: 1) PSTAR, which provides evidence-based, recovery-oriented care for individuals with persistent symptoms of psychosis, specializing in the use of clozapine, and 2) Project ARROW, a coordinated specialty care team for people experiencing prodromal and early psychosis, and 3) Youth and Family TREE, a program for youth and young adults with co-occurring disorders.
His research focuses on clozapine, pharmacologic and psychosocial interventions for people with schizophrenia, cardiometabolic side effects of antipsychotic medication, and understanding the potential for digital biomarkers in mental health.
He is Editor-In-Chief of Community Mental Health Journal.
Academic Appointment
- Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine
Education
Degrees
- MD from West Virginia University, Morgantown
- BS from Wake Forest University, Winston-Salem
Research
Publications
-
Enhancing social cognition in psychosis - the potential role of open dialogue.
Schizophrenia (Heidelb) Volume: 11 Page(s): 84
06/05/2025 Authors: Gariup M; Bergstrm T; Saliger K; Palanci JM; Cotes RO; Stoklosa JB; Seikkula J -
FDA Eliminates the Clozapine REMS-What Comes Next?
JAMA Psychiatry
06/04/2025 Authors: Kelly DL; Kane JM; Love RC; Cotes RO -
Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019-2023.
Psychiatr Serv Volume: 76 Page(s): 606 - 610
06/01/2025 Authors: Bunting SR; Cotes RO; Gray K; Chalmers K; Nguyen TD -
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.
J Clin Psychopharmacol Volume: 45 Page(s): 197 - 218
05/01/2025 Authors: de Leon J; Baldessarini RJ; Balon R; Bilbily J; Caroff SN; Citrome L; Correll CU; Cotes RO; Davis JM; DeLisi LE -
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.
J Clin Psychopharmacol Volume: 45 Page(s): 179 - 196
05/01/2025 Authors: de Leon J; Baldessarini RJ; Balon R; Bilbily J; Caroff SN; Citrome L; Correll CU; Cotes RO; Davis JM; DeLisi LE -
A model for timely dissemination of critical information: Clozapine toxicity during the COVID pandemic.
Ment Health Clin Volume: 15 Page(s): 30 - 35
02/01/2025 Authors: Gannon J; Chengappa KNR; Cotes RO; Leung JG; Frailey P; Piechowicz M; Kistler E; Nathaniel V; Eldredge C; Alessandro J -
Clozapine's High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies-How Do We Get There?
Am J Psychiatry Volume: 181 Page(s): 851 - 853
10/01/2024 Authors: Chengappa KNR; Cotes RO -
Postcrisis Follow-Up and Linkage to Community Services.
Psychiatr Clin North Am Volume: 47 Page(s): 531 - 546
09/01/2024 Authors: McClanahan A; Adams CN; Hackman AL; Cotes RO; Minkoff K -
Evaluating and mitigating unfairness in multimodal remote mental health assessments.
PLOS Digit Health Volume: 3 Page(s): e0000413
07/01/2024 Authors: Jiang Z; Seyedi S; Griner E; Abbasi A; Rad AB; Kwon H; Cotes RO; Clifford GD -
Multimodal Mental Health Digital Biomarker Analysis From Remote Interviews Using Facial, Vocal, Linguistic, and Cardiovascular Patterns.
IEEE J Biomed Health Inform Volume: 28 Page(s): 1680 - 1691
03/01/2024 Authors: Jiang Z; Seyedi S; Griner E; Abbasi A; Rad AB; Kwon H; Cotes RO; Clifford GD